Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C7H8NO3.Na |
| Molecular Weight | 177.1331 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C[C-]1OC(=O)N(CC=C)C1=O
InChI
InChIKey=QXGBKVKAWTZKOL-UHFFFAOYSA-N
InChI=1S/C7H8NO3.Na/c1-3-4-8-6(9)5(2)11-7(8)10;/h3H,1,4H2,2H3;/q-1;+1
Allomethadione is an anticonvulsant. It was used for the treatment of epilepsy. Allomethadione appears to have the advantage over tridione (another anticonvulsant) in not producing ataxia or gastric irritation. Photophobia is common in patients taking tridione but allomethadione did not produce photophobia. The drug causes renal damage. The compound has been marketed in Europe.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13045529
0.3 g five times a day
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
91810501
Created by
admin on Mon Mar 31 23:35:32 GMT 2025 , Edited by admin on Mon Mar 31 23:35:32 GMT 2025
|
PRIMARY | |||
|
6058-46-4
Created by
admin on Mon Mar 31 23:35:32 GMT 2025 , Edited by admin on Mon Mar 31 23:35:32 GMT 2025
|
PRIMARY | |||
|
DTXSID50412194
Created by
admin on Mon Mar 31 23:35:32 GMT 2025 , Edited by admin on Mon Mar 31 23:35:32 GMT 2025
|
PRIMARY | |||
|
X358SB601N
Created by
admin on Mon Mar 31 23:35:32 GMT 2025 , Edited by admin on Mon Mar 31 23:35:32 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD